Abstract
BackgroundAldo-keto reductase 1B10 (AKR1B10) is a secretory protein that is upregulated in breast cancer.ObjectiveThis case-controlled pilot study evaluated the serum level of AKR1B10 in healthy women and patients with a localized or metastatic breast cancer.MethodsAKR1B10 levels were measured by ELISA and IHC in several patient cohorts.ResultsOur data showed that serum AKR1B10 was significantly elevated in patients with localized (6.72 ± 0.92 ng/ml) or metastatic (7.79 ± 1.13 ng/ml) disease compared to cancer-free healthy women (1.69 ± 0.17 ng/ml) (p<0.001); the serum AKR1B10 was correlated with its expression in tumor tissues, but not with the tumor burden, molecular subtypes or histological stages. After surgical removal of primary tumors, the serum AKR1B10 was rapidly decreased within 3 days and plateaued at a level similar to that of healthy controls in most patients. ROC curve analysis suggested the optimal diagnostic cut-off value of serum AKR1B10 at 3.456 ng/ml with AUC 0.9045 ± 0.0337 (95% CI 0.8384 – 0.9706), sensitivity 84.75% (95% CI 73.01% to 92.78%), and specificity 93.88% (95% CI 83.13% to 98.72%).ConclusionsThese data indicate the potential value of serum AKR1B10 as a biomarker of breast cancer.
Highlights
Over 230,000 new invasive breast cancer cases are diagnosed in the United States annually, of which approximately 67% are in need of adjuvant chemotherapy treatment [1]
In mice, targeted disruption of AKR1B8, an orthologue of human Aldo-keto reductase 1B10 (AKR1B10), leads to abnormalities of intestinal epithelial self-renewal and high susceptibility to dextran sulfate sodium (DSS)-induced colitis and associated tumorigenesis [32]. In this case-controlled pilot study, we evaluated the serum levels of AKR1B10 in healthy women and patients with a localized and metastatic breast cancer
We evaluated the diagnostic values of the serum AKR1B10, and our data suggested the potential of serum AKR1B10 as a novel biomarker of breast cancer
Summary
Over 230,000 new invasive breast cancer cases are diagnosed in the United States annually, of which approximately 67% are in need of adjuvant chemotherapy treatment [1]. The American Society of Clinical Oncology (ASCO) does not recommend using CA 27.29, CA 15-3 or CEA for screening, diagnosis, and staging of breast cancer, or for monitoring response to treatment or recurrence after primary breast cancer therapy [8]. An urgent need exists for identification and validation of novel serum markers for breast cancer across the spectrum of disease, from screening and early detection to response monitoring during treatment. Objective: This case-controlled pilot study evaluated the serum level of AKR1B10 in healthy women and patients with a localized or metastatic breast cancer. Results: Our data showed that serum AKR1B10 was significantly elevated in patients with localized (6.72 ± 0.92 ng/ml) or metastatic (7.79 ± 1.13 ng/ml) disease compared to cancer-free healthy women (1.69 ± 0.17 ng/ml) (p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
